ABSTRACT
The first 1000 days of life constitute a short and exceptionally important period when the foundation is established for children's growth, development and lifelong health. Cuba has a comprehensive care system for this population that aims to promote the best start in life so that children can reach their highest development potential. This is carried out through the national public health and education systems and also includes elements of health protection, prevention of harm and disease and social welfare for children.
Subject(s)
Child Health Services , Comprehensive Health Care , Child Development , Comprehensive Health Care/methods , Cuba , Female , Humans , Infant , Infant Health , Infant, Newborn , Maternal Health Services , PregnancyABSTRACT
Se realizó una actualización sobre el uso de las sustancias más utilizadas en el reemplazo de volumen. Se plantea que la controversia entre el uso de cristaloides/coloides aún mantiene vigencia, aunque se trata de hallar la sustancia ideal que restablezca la volemia de forma adecuada, con el mínimo de reacciones adversas y costo. Dentro de los coloides se enfatizó en las desventajas del uso de la albúmina y su sustitución por otros expansores de volumen de tipo coloide, donde se encuentran las gelatinas y los almidones. Otro tipo de sustancias transportadoras de oxígeno están en fase de ensayo clínico, como son los fluorocarbonos y las hemoglobinas sintéticas, sin que se haya encontrado superioridad de tipo terapéutico.
An updating on the most used substances in volume therapy is made. It is stated that the controversy aroused by the use of crystalloids/colloids is still standing, although efforts are made to find the ideal substance to reestablish volemia in an appropiate way with the minimum of adverse reactions and cost. As regards colloids, emphasis is made on the disadvantages of the use of albumin and its substitution by other colloid volume expanders, such as gelatins and starches. Other types of oxygen transporting substances as fluorocarbons and synthetic haemoglobins are under clinical assay. No therapeutic superiority has been found yet.
